Join Erasca for a virtual investor event where management will provide a research and development (R&D) update on naporafenib and the RAS targeting franchise.

The event will discuss naporafenib (a potential first-in-class and best-in-class pan-RAF inhibitor), including preliminary SEACRAFT-1 Phase 1 data for naporafenib plus trametinib (MEKINIST^®) in patients with locally advanced unresectable or metastatic solid tumor malignancies with RAS Q61X mutations that will be presented at the 36th EORTC-NCI-AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics taking place October 23-25 in Barcelona, Spain.

The event will also highlight Erasca’s RAS targeting franchise of ERAS-0015 (a pan-RAS molecular glue that demonstrated 5- to 10-fold greater in vitro and in vivo potency and favorable ADME properties and PK properties in multiple animal species relative to another pan-RAS molecular glue currently in clinical development) and ERAS-4001 (a potent and selective inhibitor of KRAS that has the potential to provide an improved therapeutic window relative to RAS inhibitors and prevent KRAS wildtype-mediated resistance relative to mutant-selective approaches).

A live question and answer session will follow the formal presentation.